Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, With Asthma and Cystic Fibrosis Leading the Way - Research and Markets

Research and Markets
Posted on: 15 Sep 16

Research and Markets has announced the addition of the "Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way" report to their offering.

The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options can be diverse in terms of their targets and mechanisms of action. This is most notable in CF, where patients may be prescribed a combination of drugs from several treatment categories, including mucolytic agents, bronchodilators and antibiotics. The COPD and asthma treatment landscapes employ similar symptomatic treatments, including bronchodilators and inhaled corticosteroids.

However, over the past decade the treatment of respiratory disorders has developed significantly, as has the importance for novel therapies and targeted therapies. The approval of the products Orkambi and Kalydeco, in 2014 and 2012 respectively, gave patients disease-modifying treatment options for CF. Another important entry was the first biologic drug - omalizumab - approved in 2014 for the treatment of severe asthma. The trend of developing targeted therapies continued with the approval of the maintenance treatment Nucala (mepolizumab) in November 2015.

Although the more traditional non-specific symptomatic therapies continue to have a strong presence in the respiratory disorder pipeline, the pipeline also contains promising targeted biologic therapies, which reflects their growing prominence in this therapy area. Overall, 908 products are currently in active development for respiratory disorders.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Key Marketed Products

3.1 Overview

3.2 Advair - GSK

3.3 Spiriva - Boehringer Ingelheim, Pfizer

3.4 Symbicort - AstraZeneca/Astellas

3.5 Singulair (montelukast) - Merck & Co.

3.6 Flixotide/Flovent - GSK

3.7 Ventolin - GSK

3.8 Kalydeco - Vertex

3.9 Pulmozyme - Roche

3.10 Esbriet - Roche

3.11 TOBI - Novartis

3.12 Conclusion

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2022

5.1 Overall Market Size

5.2 Generic Penetration

5.3 Revenue Forecast by Molecular Target

5.4 Assessment of Key Pipeline Products

5.4.1 Dupilumab - Regeneron Pharmaceuticals/Sanofi

5.4.2 Benralizumab - AstraZeneca/Medimmune

5.4.3 Lebrikizumab - Roche/Genentech

5.4.4 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics

5.4.5 Tralokinumab - AstraZeneca

5.4.6 Batefenterol - GSK/Theravance

5.4.7 Conclusion

6 Company Analysis and Positioning

6.1 Revenue and Market Share Analysis by Company

6.1.1 GlaxoSmithKline

6.1.2 Vertex

6.1.3 AstraZeneca

6.1.4 Roche

6.1.5 Novartis

6.1.6 Boehringer Ingelheim

6.2 Company Landscape

6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

7.1 Licensing Deals

7.2 Co-development Deals

8 Appendix

For more information about this report visit

Related Topics: Respiratory Drugs, Endocrine and Metabolic Disorder Drugs, Asthma Drugs

View source version on

Business Wire

Last updated on: 15/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.